Perhaps among the most name-recognition SBIR participants, ABIOMED was acquired in late December 2022 by Johnson & Johnson - in a deal closed for $16.6B. Involved in SBIR from the very earliest days - of the firm and of the program - and remaining SBIR involved until 2014, ABIOMED, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. The firm develops and offers mechanical circulatory support devices and provides a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. More recently - 2017-18 - ABIOMED has made investment (with others) in four promising small firms in development space of interest to them ... so far none being themselves SBIR involved
